 Viralkumar Shah
Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 96 | 2025 | 3622 | 14.420 |
Why?
| | Hypoglycemic Agents | 50 | 2025 | 1219 | 8.990 |
Why?
| | Blood Glucose | 64 | 2025 | 2071 | 7.240 |
Why?
| | Blood Glucose Self-Monitoring | 48 | 2025 | 601 | 7.070 |
Why?
| | Hypoglycemia | 25 | 2025 | 424 | 5.440 |
Why?
| | Insulin | 40 | 2025 | 2313 | 5.310 |
Why?
| | Insulin Infusion Systems | 26 | 2025 | 362 | 5.100 |
Why?
| | Diabetes Mellitus, Type 2 | 21 | 2025 | 2421 | 4.100 |
Why?
| | Insulin Glargine | 7 | 2025 | 81 | 3.040 |
Why?
| | Osteoporotic Fractures | 6 | 2020 | 57 | 2.620 |
Why?
| | Pancreas, Artificial | 4 | 2023 | 70 | 2.560 |
Why?
| | Bone Density | 11 | 2025 | 463 | 2.440 |
Why?
| | Fractures, Bone | 8 | 2024 | 395 | 2.370 |
Why?
| | Biosimilar Pharmaceuticals | 4 | 2023 | 20 | 2.230 |
Why?
| | Diabetes Mellitus | 8 | 2024 | 988 | 2.110 |
Why?
| | Diabetic Ketoacidosis | 4 | 2022 | 196 | 2.080 |
Why?
| | Hyperglycemia | 8 | 2024 | 325 | 2.060 |
Why?
| | Adult | 80 | 2025 | 35505 | 1.910 |
Why?
| | Insulin Aspart | 4 | 2023 | 26 | 1.720 |
Why?
| | Humans | 129 | 2025 | 129527 | 1.600 |
Why?
| | Consensus | 4 | 2024 | 622 | 1.540 |
Why?
| | Hyperparathyroidism, Primary | 5 | 2014 | 7 | 1.510 |
Why?
| | Middle Aged | 53 | 2025 | 31087 | 1.290 |
Why?
| | Diabetes Complications | 4 | 2020 | 219 | 1.280 |
Why?
| | Peptides | 2 | 2025 | 925 | 1.270 |
Why?
| | Femur Neck | 4 | 2022 | 60 | 1.220 |
Why?
| | Young Adult | 40 | 2025 | 12438 | 1.180 |
Why?
| | Male | 66 | 2025 | 63586 | 1.140 |
Why?
| | Female | 68 | 2025 | 68650 | 1.120 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2024 | 92 | 1.080 |
Why?
| | Cannabis | 3 | 2022 | 461 | 0.940 |
Why?
| | Marijuana Abuse | 2 | 2019 | 233 | 0.930 |
Why?
| | Liraglutide | 1 | 2024 | 29 | 0.920 |
Why?
| | Glucose | 6 | 2023 | 996 | 0.910 |
Why?
| | Diabetic Retinopathy | 2 | 2024 | 179 | 0.910 |
Why?
| | Obesity | 4 | 2025 | 2875 | 0.850 |
Why?
| | Adolescent | 33 | 2025 | 20409 | 0.850 |
Why?
| | Insulin, Long-Acting | 3 | 2021 | 62 | 0.830 |
Why?
| | Registries | 10 | 2021 | 1902 | 0.820 |
Why?
| | Sweetening Agents | 1 | 2023 | 40 | 0.820 |
Why?
| | Bone and Bones | 2 | 2023 | 295 | 0.810 |
Why?
| | Risk Factors | 17 | 2024 | 9779 | 0.810 |
Why?
| | Bone Remodeling | 2 | 2020 | 71 | 0.800 |
Why?
| | Gastroparesis | 2 | 2019 | 9 | 0.780 |
Why?
| | Cardiovascular Diseases | 6 | 2022 | 1997 | 0.770 |
Why?
| | Vitamin D | 3 | 2014 | 379 | 0.770 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.760 |
Why?
| | RNAi Therapeutics | 1 | 2021 | 4 | 0.750 |
Why?
| | Hyperoxaluria, Primary | 1 | 2021 | 14 | 0.740 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.740 |
Why?
| | Patient Satisfaction | 2 | 2025 | 636 | 0.730 |
Why?
| | Treatment Outcome | 14 | 2025 | 10232 | 0.730 |
Why?
| | Automobile Driving | 1 | 2023 | 140 | 0.710 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2024 | 260 | 0.690 |
Why?
| | Osteoporosis | 3 | 2020 | 231 | 0.690 |
Why?
| | Incretins | 1 | 2020 | 18 | 0.680 |
Why?
| | Blindness | 1 | 2020 | 38 | 0.670 |
Why?
| | Feasibility Studies | 1 | 2024 | 869 | 0.660 |
Why?
| | Diabetes, Gestational | 1 | 2024 | 308 | 0.660 |
Why?
| | Self-Management | 2 | 2020 | 159 | 0.660 |
Why?
| | Bone Resorption | 1 | 2020 | 79 | 0.650 |
Why?
| | Hip Fractures | 1 | 2020 | 83 | 0.630 |
Why?
| | Age Factors | 6 | 2020 | 3150 | 0.620 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2019 | 39 | 0.610 |
Why?
| | Aged | 26 | 2025 | 22063 | 0.610 |
Why?
| | Osteogenesis | 1 | 2020 | 175 | 0.600 |
Why?
| | Absorptiometry, Photon | 5 | 2025 | 246 | 0.600 |
Why?
| | Self Care | 2 | 2018 | 366 | 0.580 |
Why?
| | Parathyroid Hormone | 4 | 2014 | 105 | 0.570 |
Why?
| | Bone Diseases | 1 | 2018 | 57 | 0.570 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 261 | 0.560 |
Why?
| | Quality of Life | 4 | 2024 | 2694 | 0.550 |
Why?
| | Drugs, Investigational | 1 | 2017 | 32 | 0.530 |
Why?
| | Calcium | 6 | 2014 | 1208 | 0.510 |
Why?
| | Marijuana Smoking | 1 | 2019 | 247 | 0.500 |
Why?
| | Fractures, Spontaneous | 1 | 2015 | 11 | 0.500 |
Why?
| | Accidental Falls | 1 | 2018 | 169 | 0.500 |
Why?
| | Child | 22 | 2025 | 20932 | 0.480 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 2 | 2025 | 14 | 0.470 |
Why?
| | Vitamin D Deficiency | 2 | 2014 | 177 | 0.470 |
Why?
| | Retrospective Studies | 13 | 2024 | 14532 | 0.470 |
Why?
| | Cross-Sectional Studies | 9 | 2025 | 5078 | 0.440 |
Why?
| | Gallstones | 1 | 2014 | 31 | 0.430 |
Why?
| | Prospective Studies | 10 | 2025 | 7150 | 0.420 |
Why?
| | Glucose Intolerance | 1 | 2015 | 142 | 0.420 |
Why?
| | Insulin Lispro | 2 | 2024 | 39 | 0.420 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 46 | 0.410 |
Why?
| | Body Mass Index | 5 | 2025 | 2269 | 0.410 |
Why?
| | Pancreatitis | 1 | 2014 | 124 | 0.400 |
Why?
| | Suicide | 1 | 2020 | 613 | 0.400 |
Why?
| | Sex Factors | 5 | 2025 | 1966 | 0.370 |
Why?
| | Bone Diseases, Metabolic | 3 | 2019 | 57 | 0.370 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 186 | 0.370 |
Why?
| | Diabetic Angiopathies | 3 | 2020 | 256 | 0.360 |
Why?
| | Autoimmune Diseases | 1 | 2015 | 428 | 0.360 |
Why?
| | Meals | 3 | 2024 | 119 | 0.350 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 5429 | 0.350 |
Why?
| | Sex Characteristics | 3 | 2025 | 734 | 0.340 |
Why?
| | Benchmarking | 2 | 2022 | 175 | 0.320 |
Why?
| | Weight Loss | 2 | 2024 | 738 | 0.310 |
Why?
| | United States | 9 | 2024 | 13865 | 0.290 |
Why?
| | Autoantibodies | 2 | 2018 | 1468 | 0.290 |
Why?
| | Diabetic Nephropathies | 2 | 2024 | 284 | 0.290 |
Why?
| | Prevalence | 5 | 2023 | 2561 | 0.280 |
Why?
| | Reference Values | 2 | 2019 | 795 | 0.270 |
Why?
| | India | 4 | 2015 | 171 | 0.270 |
Why?
| | Phenotype | 1 | 2015 | 3058 | 0.270 |
Why?
| | Risk Assessment | 3 | 2020 | 3255 | 0.260 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2724 | 0.260 |
Why?
| | Case-Control Studies | 5 | 2025 | 3383 | 0.250 |
Why?
| | Cross-Over Studies | 4 | 2024 | 522 | 0.240 |
Why?
| | Manitoba | 1 | 2024 | 2 | 0.230 |
Why?
| | Thyrotoxicosis | 1 | 2024 | 9 | 0.230 |
Why?
| | Phosphates | 3 | 2014 | 181 | 0.220 |
Why?
| | Follow-Up Studies | 3 | 2025 | 4891 | 0.220 |
Why?
| | Algorithms | 3 | 2024 | 1614 | 0.220 |
Why?
| | Proof of Concept Study | 1 | 2024 | 69 | 0.220 |
Why?
| | Artificial Organs | 1 | 2023 | 2 | 0.210 |
Why?
| | Germany | 2 | 2020 | 100 | 0.210 |
Why?
| | Glycemic Index | 1 | 2022 | 25 | 0.200 |
Why?
| | History, 20th Century | 2 | 2014 | 295 | 0.200 |
Why?
| | Minority Groups | 2 | 2023 | 250 | 0.190 |
Why?
| | Reproducibility of Results | 5 | 2024 | 3081 | 0.190 |
Why?
| | Aged, 80 and over | 5 | 2021 | 7052 | 0.190 |
Why?
| | Vision Screening | 1 | 2021 | 9 | 0.190 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2022 | 35 | 0.190 |
Why?
| | Pregnancy | 3 | 2024 | 6412 | 0.190 |
Why?
| | Gastric Emptying | 1 | 2021 | 38 | 0.180 |
Why?
| | Computer Systems | 2 | 2018 | 44 | 0.180 |
Why?
| | Calibration | 2 | 2018 | 140 | 0.180 |
Why?
| | Body Composition | 1 | 2025 | 649 | 0.180 |
Why?
| | Biomarkers | 3 | 2023 | 3968 | 0.180 |
Why?
| | Diabetic Neuropathies | 1 | 2022 | 94 | 0.180 |
Why?
| | Prediabetic State | 1 | 2024 | 244 | 0.180 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2020 | 2 | 0.170 |
Why?
| | Regression Analysis | 2 | 2020 | 994 | 0.170 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2020 | 19 | 0.170 |
Why?
| | Austria | 1 | 2020 | 5 | 0.170 |
Why?
| | Vision Disorders | 1 | 2021 | 135 | 0.170 |
Why?
| | Energy Intake | 1 | 2023 | 462 | 0.170 |
Why?
| | Societies, Medical | 1 | 2024 | 757 | 0.170 |
Why?
| | Skiing | 1 | 2021 | 44 | 0.170 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1842 | 0.170 |
Why?
| | Psychometrics | 2 | 2021 | 696 | 0.160 |
Why?
| | Glucagon-Secreting Cells | 1 | 2020 | 24 | 0.160 |
Why?
| | RNA Interference | 1 | 2021 | 450 | 0.160 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 146 | 0.160 |
Why?
| | Body Weight | 1 | 2024 | 941 | 0.160 |
Why?
| | Insulin Antibodies | 1 | 2020 | 105 | 0.160 |
Why?
| | Bone Development | 1 | 2019 | 50 | 0.160 |
Why?
| | Postprandial Period | 1 | 2020 | 104 | 0.160 |
Why?
| | Fatal Outcome | 1 | 2020 | 300 | 0.160 |
Why?
| | C-Peptide | 1 | 2020 | 155 | 0.160 |
Why?
| | Radius | 1 | 2019 | 35 | 0.150 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2021 | 22 | 0.150 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 209 | 0.150 |
Why?
| | Healthy Volunteers | 1 | 2019 | 199 | 0.150 |
Why?
| | Infusion Pumps, Implantable | 1 | 2018 | 23 | 0.150 |
Why?
| | Cancellous Bone | 1 | 2018 | 21 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2021 | 245 | 0.150 |
Why?
| | Methyldopa | 1 | 2018 | 7 | 0.150 |
Why?
| | Social Class | 1 | 2020 | 258 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1368 | 0.150 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 37 | 0.140 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 234 | 0.140 |
Why?
| | Postmenopause | 1 | 2020 | 349 | 0.140 |
Why?
| | Tibia | 1 | 2019 | 168 | 0.140 |
Why?
| | Health Behavior | 1 | 2023 | 742 | 0.140 |
Why?
| | Health Status Disparities | 1 | 2020 | 256 | 0.140 |
Why?
| | Coronavirus Infections | 1 | 2022 | 336 | 0.140 |
Why?
| | HLA-DQ Antigens | 1 | 2018 | 179 | 0.140 |
Why?
| | Time Factors | 3 | 2023 | 6530 | 0.140 |
Why?
| | Pelvic Bones | 1 | 2020 | 156 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2018 | 207 | 0.130 |
Why?
| | Computer-Aided Design | 1 | 2017 | 42 | 0.130 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1037 | 0.130 |
Why?
| | Uric Acid | 1 | 2018 | 161 | 0.130 |
Why?
| | Glucagon | 1 | 2017 | 105 | 0.130 |
Why?
| | Biosensing Techniques | 1 | 2018 | 118 | 0.130 |
Why?
| | Hormones | 1 | 2017 | 140 | 0.130 |
Why?
| | Antibody Formation | 1 | 2018 | 291 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1510 | 0.130 |
Why?
| | Pregnancy in Diabetics | 1 | 2018 | 118 | 0.130 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 146 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 265 | 0.130 |
Why?
| | Referral and Consultation | 1 | 2021 | 732 | 0.130 |
Why?
| | Health Personnel | 1 | 2022 | 654 | 0.130 |
Why?
| | Drug Design | 1 | 2017 | 157 | 0.120 |
Why?
| | Circadian Rhythm | 1 | 2019 | 416 | 0.120 |
Why?
| | Alkaline Phosphatase | 2 | 2014 | 146 | 0.120 |
Why?
| | Drug Overdose | 1 | 2020 | 326 | 0.120 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 367 | 0.120 |
Why?
| | Energy Metabolism | 1 | 2020 | 864 | 0.110 |
Why?
| | Parathyroidectomy | 1 | 2014 | 8 | 0.110 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.110 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 8 | 0.110 |
Why?
| | Allylamine | 1 | 2013 | 8 | 0.110 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2013 | 10 | 0.110 |
Why?
| | Bromocriptine | 1 | 2013 | 29 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2018 | 532 | 0.110 |
Why?
| | Insulin Detemir | 1 | 2013 | 8 | 0.110 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2014 | 58 | 0.110 |
Why?
| | History, 21st Century | 1 | 2014 | 186 | 0.110 |
Why?
| | Insulin, Isophane | 1 | 2013 | 21 | 0.110 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 45 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2734 | 0.100 |
Why?
| | Islet Amyloid Polypeptide | 1 | 2013 | 46 | 0.100 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 107 | 0.100 |
Why?
| | Bionics | 2 | 2023 | 12 | 0.100 |
Why?
| | Mutation | 1 | 2024 | 3702 | 0.100 |
Why?
| | Parathyroid Neoplasms | 1 | 2012 | 12 | 0.100 |
Why?
| | Recurrence | 1 | 2016 | 1011 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2013 | 137 | 0.100 |
Why?
| | Abdominal Pain | 1 | 2014 | 142 | 0.100 |
Why?
| | Suppuration | 1 | 2012 | 9 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 172 | 0.100 |
Why?
| | Cohort Studies | 2 | 2020 | 5423 | 0.100 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2013 | 114 | 0.100 |
Why?
| | Hypoparathyroidism | 1 | 2012 | 4 | 0.100 |
Why?
| | Dogs | 1 | 2013 | 385 | 0.100 |
Why?
| | Leptin | 1 | 2013 | 222 | 0.100 |
Why?
| | Diabetic Foot | 1 | 2012 | 24 | 0.100 |
Why?
| | Hemoglobins | 1 | 2014 | 337 | 0.100 |
Why?
| | Soft Tissue Infections | 1 | 2012 | 36 | 0.090 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2012 | 90 | 0.090 |
Why?
| | Cholelithiasis | 1 | 2011 | 36 | 0.090 |
Why?
| | Swine | 1 | 2013 | 760 | 0.090 |
Why?
| | Biomedical Research | 1 | 2017 | 639 | 0.090 |
Why?
| | Adenoma | 1 | 2012 | 211 | 0.090 |
Why?
| | Osteomyelitis | 1 | 2012 | 121 | 0.080 |
Why?
| | Animals | 4 | 2018 | 35334 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2143 | 0.080 |
Why?
| | Metformin | 1 | 2013 | 316 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1935 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4403 | 0.080 |
Why?
| | Exercise | 1 | 2020 | 1931 | 0.070 |
Why?
| | Pilot Projects | 3 | 2021 | 1594 | 0.070 |
Why?
| | Staphylococcal Infections | 1 | 2012 | 391 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1283 | 0.070 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 55 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1211 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2023 | 99 | 0.050 |
Why?
| | Insulin, Regular, Human | 1 | 2022 | 43 | 0.050 |
Why?
| | Child, Preschool | 3 | 2024 | 10499 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1708 | 0.050 |
Why?
| | Needles | 1 | 2022 | 57 | 0.050 |
Why?
| | Off-Label Use | 1 | 2021 | 51 | 0.050 |
Why?
| | Reference Standards | 1 | 2021 | 176 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1029 | 0.040 |
Why?
| | Pancreas | 1 | 2023 | 304 | 0.040 |
Why?
| | Sodium | 1 | 2021 | 204 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 83 | 0.040 |
Why?
| | Inpatients | 1 | 2023 | 476 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 1001 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 287 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 167 | 0.040 |
Why?
| | Individuality | 1 | 2019 | 159 | 0.040 |
Why?
| | Hospitals | 1 | 2022 | 649 | 0.030 |
Why?
| | Skin | 1 | 2022 | 724 | 0.030 |
Why?
| | Kidney | 1 | 2024 | 1382 | 0.030 |
Why?
| | Social Determinants of Health | 1 | 2020 | 226 | 0.030 |
Why?
| | Prognosis | 1 | 2025 | 3772 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 257 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 374 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 539 | 0.030 |
Why?
| | Patient Compliance | 1 | 2020 | 567 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 587 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2024 | 1168 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 489 | 0.030 |
Why?
| | Culture | 1 | 2015 | 124 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2013 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2014 | 27 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 591 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2018 | 711 | 0.030 |
Why?
| | Home Care Services | 1 | 2017 | 244 | 0.030 |
Why?
| | Cholecalciferol | 1 | 2014 | 56 | 0.030 |
Why?
| | Calcifediol | 1 | 2012 | 31 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2135 | 0.020 |
Why?
| | Parents | 1 | 2021 | 1309 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2503 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 175 | 0.020 |
Why?
| | Research Design | 1 | 2017 | 1043 | 0.020 |
Why?
| | Tourniquets | 1 | 2011 | 20 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2012 | 349 | 0.020 |
Why?
| | Serum Albumin | 1 | 2011 | 149 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 977 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2628 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 265 | 0.020 |
Why?
| | Infant | 1 | 2019 | 9005 | 0.010 |
Why?
| | Mice | 1 | 2018 | 16973 | 0.010 |
Why?
|
|
Shah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|